[Androgen receptor-positive triple negative breast cancer: From biology to therapy].
Cancer du sein triple négatif exprimant le récepteur aux androgènes : de la biologie à la thérapeutique.
Abiraterone Acetate
/ therapeutic use
Age Factors
Aged
Androgen Antagonists
/ therapeutic use
Anilides
/ therapeutic use
Benzamides
Class I Phosphatidylinositol 3-Kinases
/ genetics
Clinical Trials as Topic
Drug Screening Assays, Antitumor
Female
Forecasting
Humans
Mutation
Nitriles
/ therapeutic use
Phenylthiohydantoin
/ analogs & derivatives
Prognosis
Rare Diseases
/ drug therapy
Receptors, Androgen
/ metabolism
Signal Transduction
Tosyl Compounds
/ therapeutic use
Triple Negative Breast Neoplasms
/ drug therapy
Anti-androgen
Anti-androgènes
Breast cancer
Cancer du sein
Triple negative androgen receptor positive tumor
Tumeurs triple négatives récepteurs androgènes positives
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
28
11
2019
revised:
24
12
2019
accepted:
26
12
2019
pubmed:
9
3
2020
medline:
7
5
2020
entrez:
9
3
2020
Statut:
ppublish
Résumé
A subgroup of androgen receptor-expressing tumors represents approximately 30 % of all triple negative tumors. The androgen receptor and its signaling pathways have a central biological role in this tumor entity. These triple negative androgen receptor-positive tumors occur in older patients and do not appear to have a better prognosis compared to other triple negative tumors. In addition to androgen receptor-expression, these tumors are genomically characterized by a high frequency of PIK3CA activating mutation. Three clinical trials reported efficacy data for anti-androgens (bicalutamide, abiraterone acetate and enzalutamide) based on strong preclinical rationale. These trials report clinical benefit rates in about one in five patients. These encouraging but still limited results make a case for the identification of predictive response factors and therapeutic combinations to improve response rates. This review will provide an update on the biological and clinical knowledge of this tumoral subgroup that opens the way to non-cytotoxic anti-androgen therapies.
Identifiants
pubmed: 32145961
pii: S0007-4551(20)30115-6
doi: 10.1016/j.bulcan.2019.12.012
pii:
doi:
Substances chimiques
AR protein, human
0
Androgen Antagonists
0
Anilides
0
Benzamides
0
Nitriles
0
Receptors, Androgen
0
Tosyl Compounds
0
Phenylthiohydantoin
2010-15-3
enzalutamide
93T0T9GKNU
bicalutamide
A0Z3NAU9DP
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Abiraterone Acetate
EM5OCB9YJ6
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
506-516Informations de copyright
Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.